-+ 0.00%
-+ 0.00%
-+ 0.00%

CannaPharmaRx Q2 FY26 net loss widens to USD 1.91 million; revenue rises 19.26% to USD 276,218

PUBT·08/18/2026 20:51:56
Listen to the news
CannaPharmaRx Q2 FY26 net loss widens to USD 1.91 million; revenue rises 19.26% to USD 276,218
  • CannaPharmaRx posted Q2 revenue of USD 276,218, up 19.26% year over year; net loss widened to USD 1.91 million.
  • Gross loss narrowed to USD 138,446 from USD 621,210, on lower inventory impairment charges of USD 218,752.
  • Other expenses climbed to USD 1.53 million, driven by a USD 1.6 million loss on derivative conversion features.
  • For the six months, revenue rose to USD 903,680; net loss widened to USD 2.29 million.
  • Liquidity remained strained with USD 555 cash, a USD 31.24 million working-capital deficit; Alberta Ltd. stayed in default under Koze’s royalty agreement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CannaPharmaRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006570), on August 18, 2026, and is solely responsible for the information contained therein.